<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="brief-report" dtd-version="2.3">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Genet.</journal-id>
<journal-title>Frontiers in Genetics</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Genet.</abbrev-journal-title>
<issn pub-type="epub">1664-8021</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fgene.2020.00050</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Genetics</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Mutation in <italic>Fbxo11</italic> Leads to Altered Immune Cell Content in <italic>Jeff</italic> Mouse Model of Otitis Media</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Vikhe</surname>
<given-names>Pratik P.</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/672536"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tateossian</surname>
<given-names>Hilda</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/693587"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bharj</surname>
<given-names>Gurpreet</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/794691"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brown</surname>
<given-names>Steve D.M.</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/882227"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hood</surname>
<given-names>Derek W.</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/848358"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>Mammalian Genetics Unit, MRC Harwell Institute</institution>, <addr-line>Oxfordshire</addr-line>, <country>United Kingdom</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Allen Frederic Ryan, University of California, San Diego, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Jian Dong Li, Georgia State University, United States; Anke Leichtle, Universit&#xe4;t zu L&#xfc;beck, Germany</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Pratik P. Vikhe, <email xlink:href="mailto:p.vikhe@har.mrc.ac.uk">p.vikhe@har.mrc.ac.uk</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Genetic Disorders, a section of the journal Frontiers in Genetics</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>02</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>50</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>07</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>01</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2020 Vikhe, Tateossian, Bharj, Brown and Hood</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Vikhe, Tateossian, Bharj, Brown and Hood</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The <italic>Jeff</italic> mouse mutant carries a mutation in the F-box only 11 gene (<italic>Fbxo11</italic>) and heterozygous animals display conductive deafness due to the development of otitis media (OM). The <italic>Fbxo11</italic> locus is also associated with chronic otitis media with effusion (COME) and recurrent OM in humans. The <italic>Jeff</italic> mutation affects the ability of FBXO11 to stabilize p53 that leads to perturbation in the TGF-beta/Smad2 signaling pathway important in immunity and inflammation. In the current study, we evaluated the effect of the <italic>Jeff</italic> mutation on the immune cell content using multicolor flow cytometry. In blood of <italic>Jeff</italic> heterozygotes, we observed a significant increase in the number of NK, dendritic (CD11b+), neutrophils, and natural killer T (NKT) cells and a significant decrease in effector T-helper and B-lymphocytes compared to wild-type controls. The percentage of NK cells significantly decreased in the lungs of <italic>Jeff</italic> heterozygotes, with a concomitant reduction in B-lymphocytes and T-cytotoxic cells. In the spleen, <italic>Jeff</italic> heterozygotes displayed a significant decrease in mature B-lymphocytes, effector T-helper, and na&#xef;ve T-cytotoxic cells. Neutrophils, dendritic, and NKT cells dominated bulla fluid in <italic>Jeff</italic> heterozygote mice. Similar analysis carried out on <italic>Fbxo11<sup>tm2b/+</sup>
</italic> heterozygotes, which carry a null allele, showed no difference when compared to wild-type. Cytokine/chemokine analysis revealed a significant increase in the G-CSF, GM-CSF, sTNFRI, TPO, and IL-7 levels in <italic>Jeff</italic> heterozygote serum compared to wild-type. This analysis increases our understanding of the role played by <italic>Fbxo11</italic>, a gene associated with human OM, in the systemic and localized cellular immune response associated with increased susceptibility to OM.</p>
</abstract>
<kwd-group>
<kwd>
<italic>Fbxo11</italic>
</kwd>
<kwd>otitis media</kwd>
<kwd>
<italic>Jeff</italic> mouse</kwd>
<kwd>immune cells</kwd>
<kwd>natural killer cells</kwd>
</kwd-group>
<contract-sponsor id="cn001">Medical Research Council<named-content content-type="fundref-id">10.13039/501100000265</named-content>
</contract-sponsor>
<counts>
<fig-count count="3"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="35"/>
<page-count count="9"/>
<word-count count="5832"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Otitis media (OM) is a very common middle ear disease in children that is characterized by middle ear inflammation and fluid accumulation (<xref ref-type="bibr" rid="B24">Schilder et&#xa0;al., 2016</xref>). Pathology of OM can manifest in different ways and chronic and recurrent OM (ROM), often accompanied by effusion (chronic OM with effusion, COME), can lead to hearing loss and developmental delays with a significant burden on the healthcare system (<xref ref-type="bibr" rid="B30">Veenhoven et&#xa0;al., 2003</xref>). Tympanostomy to alleviate COME remains the commonest cause of surgery in children. There is a significant genetic component to COME (<xref ref-type="bibr" rid="B23">Sale et&#xa0;al., 2011</xref>), and recently the discovery of a number of mouse genetic models of COME has led to insights into the genetic and molecular pathways involved in the pathophysiology of chronic middle ear disease (<xref ref-type="bibr" rid="B14">Li et&#xa0;al., 2013</xref>; <xref ref-type="bibr" rid="B3">Bhutta et&#xa0;al., 2017b</xref>). <italic>Jeff</italic> (<xref ref-type="bibr" rid="B6">Hardisty et&#xa0;al., 2003</xref>), <italic>Junbo</italic> (<xref ref-type="bibr" rid="B19">Parkinson et&#xa0;al., 2006</xref>), and <italic>edison</italic> (<xref ref-type="bibr" rid="B4">Crompton et&#xa0;al., 2017</xref>) mutants are COME mouse models each with single point mutation in the <italic>Fbxo11, Evi1,</italic> and <italic>nischarin</italic> genes respectively, identified at MRC Harwell through a deafness screen as a part of a larger scale N-ethyl-N-nitrosourea (ENU) mouse mutagenesis program (<xref ref-type="bibr" rid="B18">Nolan et&#xa0;al., 2000</xref>).</p>
<p>Following the identification of a number of genes involved in COME in the mouse there have been several studies to explore the association of these genes with COME in the human population. Association studies have shown that several human genes may increase susceptibility toward OM, including <italic>FBXO11</italic> (<xref ref-type="bibr" rid="B23">Sale et&#xa0;al., 2011</xref>). One of the largest association studies employing samples from 1,296 families (3,828 individuals) uncovered a significant link between FBXO11 and OM susceptibility (<xref ref-type="bibr" rid="B2">Bhutta et&#xa0;al., 2017a</xref>). Moreover, two similar studies carried out on western Australian children (<xref ref-type="bibr" rid="B22">Rye et&#xa0;al., 2011</xref>) and Minnesota COME/ROM families (<xref ref-type="bibr" rid="B26">Segade et&#xa0;al., 2006</xref>) showed a direct link between polymorphisms at the <italic>FBXO11</italic> locus and OM susceptibility.</p>
<p>FBXO11 is part of the SCF (SKP1-cullin-F-box) complex, a multi-protein E3 ubiquitin-ligase complex catalyzing the ubiquitination of proteins destined for proteasomal degradation. FBXO11 is involved in ubiquitination of BCL6 (<xref ref-type="bibr" rid="B5">Duan et al., 2012</xref>) and phosphorylated SNAIL (<xref ref-type="bibr" rid="B35">Zheng et&#xa0;al., 2014</xref>), and neddylation of p53 (<xref ref-type="bibr" rid="B1">Abida et&#xa0;al., 2007</xref>), which play critical roles in regulation of the mammalian cell cycle and function. FBXO11, through regulation of BCL6, modulates B-cell survival and plays a crucial role in B-cell lymphoma (<xref ref-type="bibr" rid="B5">Duan et&#xa0;al., 2012</xref>). Other than regulation of B-cell survival in lymphoma, the role played by FBXO11 in modulating other immune cells and the relevance of this to OM remains unclear.</p>
<p>In the current study, we used the well-characterized COME <italic>Jeff</italic> mouse model (<xref ref-type="bibr" rid="B6">Hardisty et&#xa0;al., 2003</xref>; <xref ref-type="bibr" rid="B7">Hardisty-Hughes et&#xa0;al., 2006</xref>) which carries a missense mutation in the <italic>Fbxo11</italic> gene. The homozygotes of this mutant mouse line do not survive beyond birth and show a severe lung phenotype (<xref ref-type="bibr" rid="B28">Tateossian et&#xa0;al., 2009</xref>), whereas the heterozygote mice survive with chronic OM (<xref ref-type="bibr" rid="B6">Hardisty et&#xa0;al., 2003</xref>). FBXO11 can function as a Nedd8-ligase for p53 promoting its neddylation and inhibiting its transcription activity. The <italic>Fbxo11</italic> mutation in the <italic>Jeff</italic> mouse results in a decreased level of p53 and increased pSmad2 levels; pSmad2 is directly involved in the regulation of the TGF-beta pathway (<xref ref-type="bibr" rid="B28">Tateossian et&#xa0;al., 2009</xref>; <xref ref-type="bibr" rid="B29">Tateossian et&#xa0;al., 2015</xref>). The TGF-beta pathway plays a critical role in maintaining homeostasis by regulating remodeling of injury in disease and modulating the immune and inflammatory response (<xref ref-type="bibr" rid="B33">Wan and Flavell, 2007</xref>).</p>
<p>The association of <italic>FBXO11</italic> locus polymorphisms with OM in the human population and the corresponding phenotype observed in the <italic>Jeff</italic> mouse with a mutation in the orthologous gene makes it a vital model to dissect important immune changes that are associated with OM. In the current study, we analyzed the cellular immune changes that occur due to the <italic>Fbxo11</italic> mutation in the heterozygote <italic>Jeff</italic> mouse using a comprehensive flow cytometry panel that classified granulocytes, monocytes, macrophages, eosinophils, dendritic, natural killer, B and T cells. The <italic>Jeff</italic> mutation significantly altered the immune cell content in the blood, mostly affecting the natural killer cells, and adaptive B and T immune cells, which underlines the significance of FBXO11 in the immune/genetic regulation of these cells. Further, we carried out a similar analysis with the heterozygote <italic>Fbxo11</italic> knockout mouse in order to better understand the role of FBXO11 in the cellular immune response. The <italic>Fbxo11</italic> knockout mouse did not show significant differences in the immune cells as was observed in the <italic>Jeff</italic> mouse, suggesting that the <italic>Fbxo11</italic> mutation in the <italic>Jeff</italic> mouse has gain of function effects that lead to altered immune cell content. Also, using a mouse model, this study is the first to report systemic immune cell differences due to a genetic aberration leading to localized middle ear inflammation and OM.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s2_1">
<title>Mice</title>
<p>The humane care and use of mice in this study was carried out under the appropriate UK Home Office license and the local ethics review committee reviewed the experimental procedures.</p>
<p>Heterozygote <italic>Fbxo11<sup>Jf/+</sup>
</italic> (also referred to as <italic>Jeff</italic> Het) mice and their <italic>Jeff</italic> wild-type littermates (also referred to as <italic>Jeff</italic> Wt) were generated by inter-crossing F1 <italic>Fbxo11<sup>Jf/+</sup>
</italic> C57BL/6J C3H/HeH males with F1 <italic>Fbxo11<sup>+/+</sup>
</italic> C57BL/6J C3H/HeH wild-type females. Heterozygote <italic>Fbxo11<sup>tm2b/+</sup>
</italic> (also referred to as <italic>Fbxo11</italic> knockout) and their <italic>Fbxo11<sup>+/+</sup>
</italic> wild-type littermates were generated by inter-crossing F1 <italic>Fbxo11<sup>tm2b/+</sup>
</italic>-PL-TM2B-C57BL/6NJ with C57BL/6NJ females. The mice were specific pathogen free and used at 8 weeks of age.</p>
</sec>
<sec id="s2_2">
<title>Sample Preparation</title>
<p>Blood was collected by retro-orbital bleeding under terminal anesthesia induced by an intraperitoneal overdose of sodium pentobarbital in lithium heparin tubes. For flow cytometry analysis, 50 &#xb5;l of blood was resuspended in 1 ml of red blood cell (RBC) lysis buffer (Biolegend&#x2122;) for 10 min on ice followed by centrifugation and two washes with 1 ml phosphate buffer saline (PBS). The final pellet was resuspended in FACS buffer (5 mM EDTA, 0.5% fetal calf serum in PBS). Middle ear fluid for flow cytometry and cytokine/chemokine analyses was collected as described previously (<xref ref-type="bibr" rid="B31">Vikhe et&#xa0;al., 2019</xref>). Briefly, middle ear fluid was collected from unskinned heads obtained from mice under terminal anesthesia. After removal of any material on the external surface of the tympanic membrane, a hole was made in the membrane while removing the malleus from the middle ear using a sterile pair of forceps and fluid was collected with a pipette and microtip in 10 &#x3bc;l cold PBS. Other tissues (spleens and lungs) were collected in gentleMACS&#x2122; C tubes with 3 ml RPMI supplemented with 10 &#xb5;g/ml collagenase II (Serlabo&#x2122;) and 166 &#xb5;g/ml DNAse I (Sigma&#x2122;). The tissue was homogenized in a gentleMACS&#x2122; Dissociator and the single cell suspension was separated from tissue debris by passing through a 70 &#xb5;m Cell Strainer. The cell pellet obtained after centrifugation at 800 x g for 2 min was resuspended in RBC lysis buffer. Finally, after RBC lysis, the cells were pelleted by centrifugation then resuspended in FACS buffer for flow cytometry analysis.</p>
</sec>
<sec id="s2_3">
<title>Flow Cytometry Analysis</title>
<p>Middle ear fluid, blood, lung, and spleen samples were diluted with FACS buffer, and a cell count was obtained. The samples were transferred to a 96 well plate at the concentration of 2 X 10<sup>5</sup> cells/well. Cells were centrifuged and washed twice with FACS buffer. For the analysis of different types of immune cells, the resuspended cells were incubated for 15 min with CD16/CD32 antibody (BD Pharmagen&#x2122;) at a dilution of 1:100. After centrifugation at 800 x g for 1 min, cell pellets were resuspended in 100 &#xb5;l of either of panel 1 or panel 2 (<xref ref-type="supplementary-material" rid="SM3">
<bold>Table S1</bold>
</xref>) antibody cocktail and incubated for 20 min in the dark. Cells were centrifuged and washed twice with FACS buffer and finally resuspended in 100 &#xb5;l of Sytox DNA stain (1:10,000). After making up the final volume to 250 &#xb5;l with FACS buffer, flow cytometry was performed using a BD FACSCanto&#x2122; II system. FlowJo software (Tree Star&#x2122;) was used to analyze the data obtained (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figures S1</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM2">
<bold>S2</bold>
</xref> and <xref ref-type="supplementary-material" rid="SM4">
<bold>Table S2</bold>
</xref>).</p>
</sec>
<sec id="s2_4">
<title>Cytokine/Chemokine Analysis</title>
<p>Cytokine and chemokine levels were measured using a mouse cytokine antibody array (Mouse Cytokine Array C1, RayBiotech Inc.&#x2122;) as described previously (<xref ref-type="bibr" rid="B31">Vikhe et&#xa0;al., 2019</xref>). Changes in IL-7 and IL-15 were analyzed by Mouse IL-7 and IL-15 DuoSet ELISA (R&amp;D systems&#x2122;) according to the manufacturer's instructions. The color change was measured at 450 nm on an Epoch BioTek&#x2122; plate reader and the IL-7 and IL-15 concentrations were calculated by using the standard curve obtained.</p>
</sec>
<sec id="s2_5">
<title>Data Analysis</title>
<p>We used the unpaired t test assuming equal variance for comparing the cytokine/chemokine changes between <italic>Fbxo11<sup>Jf/+</sup>
</italic> serum to the <italic>Jeff</italic> wild-type whereas non-parametric Mann-Whitney U test was used to compare the flow cytometry data. A <italic>P</italic> value of less than 0.05 was considered significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Innate Immune Cell Population in <italic>Fbxo11<sup>Jf/+</sup>
</italic> Mouse</title>
<p>Innate immune cells play a critical role in the initiation of the inflammatory response and the onset and maintenance of OM (<xref ref-type="bibr" rid="B17">Mittal et&#xa0;al., 2014</xref>). The <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse is characterized by middle ear inflammation that mimics the human OM and also exhibits a defective lung phenotype (<xref ref-type="bibr" rid="B28">Tateossian et&#xa0;al., 2009</xref>). To understand the effect of the <italic>Jeff</italic> mutation in the <italic>Fbxo11</italic> gene on the innate immune cell population we analyzed the neutrophils, eosinophils, macrophages, monocytes, dendritic cells (DC) (CD11b+ve and &#x2013;ve), progenitor DC, and natural killer (NK) cells present in blood, spleen, lungs, and middle ear fluids obtained from the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). Significant differences were observed in the proportion of blood neutrophils, macrophages, DCs, and NK cells in <italic>Fbxo11<sup>Jf/+</sup>
</italic> when compared to the <italic>Jeff</italic> wild-type litter mates. The greatest difference was observed in blood NK cell levels, which were 10.84% of live cells in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse compared to 5.87% in the <italic>Jeff</italic> wild-type counterpart (<xref ref-type="fig" rid="f1">
<bold>Figure 1A&#x2013;C</bold>
</xref>). The <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse had 3.31% of CD11b+ve DCs compared to 1.29% present in <italic>Jeff</italic> wild-type blood. Similarly, slight but significantly higher levels of macrophages (0.57%) were observed in <italic>Fbxo11<sup>Jf/+</sup>
</italic> compared to 0.20% in <italic>Jeff</italic> wild-type blood. Blood granulocyte levels were significantly higher in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> (19.30%) compared to <italic>Jeff</italic> wild-type (16.60%) mouse. In contrast to blood, a significantly lower proportion of NK cells was observed in lungs of <italic>Fbxo11<sup>Jf/+</sup>
</italic> (0.91%) compared to <italic>Jeff</italic> wild-type (2.80%) mice. Further, <italic>Fbxo11<sup>Jf/+</sup>
</italic> lungs had 0.81% of monocytes compared to 1.58% in the <italic>Jeff</italic> wild-type mouse. No significant difference was observed in <italic>Fbxo11<sup>Jf/+</sup>
</italic> spleen innate immune cells when compared to the <italic>Jeff</italic> wild-type mouse. The middle ear fluid from <italic>Fbxo11<sup>Jf/+</sup>
</italic> had a high percentage of granulocytes and DCs. The middle ear fluid comprised 10.34% neutrophils and 6.69% progenitor dendritic cells (pDCs). Compared to pDC's, the percentage of CD11b-ve DCs and CD11b+ DCs in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> middle ear fluid was less: 3.69 and 4.54% respectively (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Immune cell percentage in <italic>Jeff</italic> wild-type (<italic>Jeff</italic> Wt) and <italic>Fbxo11<sup>Jf/+</sup>
</italic> (<italic>Jeff</italic> Het) mouse obtained by flow cytometry.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Immune cells</th>
<th valign="top" colspan="2" align="center">Blood</th>
<th valign="top" colspan="2" align="center">Lungs</th>
<th valign="top" colspan="2" align="center">Spleen</th>
<th valign="top" align="center">MEF</th>
</tr>
<tr>
<th valign="top"/>
<th valign="top" align="center">
<italic>Jeff</italic> Wt</th>
<th valign="top" align="center">
<italic>Jeff</italic> Het</th>
<th valign="top" align="center">
<italic>Jeff</italic> Wt</th>
<th valign="top" align="center">
<italic>Jeff</italic> Het</th>
<th valign="top" align="center">
<italic>Jeff</italic> Wt</th>
<th valign="top" align="center">
<italic>Jeff</italic> Het</th>
<th valign="top" align="center">
<italic>Jeff</italic> Het</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<bold>Granulocytes</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>16.60 ( &#xb1; 1.76)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>19.30 ( &#xb1; 0.85)</bold>
</td>
<td valign="top" align="center">6.21 ( &#xb1; 0.79)</td>
<td valign="top" align="center">5.34 ( &#xb1; 0.43)</td>
<td valign="top" align="center">3.53 ( &#xb1; 0.43)</td>
<td valign="top" align="center">2.77 ( &#xb1; 0.31)</td>
<td valign="top" align="center">10.34 ( &#xb1; 4.11)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Eosinophils</bold>
</td>
<td valign="top" align="center">0.18 ( &#xb1; 0.07)</td>
<td valign="top" align="center">0.29 ( &#xb1; 0.05)</td>
<td valign="top" align="center">0.035 ( &#xb1; 0.01)</td>
<td valign="top" align="center">0.028 ( &#xb1; 0.01)</td>
<td valign="top" align="center">0.05 ( &#xb1; 0.03)</td>
<td valign="top" align="center">0.021 ( &#xb1; 0.01)</td>
<td valign="top" align="center">0.14 ( &#xb1; 0.05)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Macrophages</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>0.20 ( &#xb1; 0.06)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>0.57 ( &#xb1; 0.16)</bold>
</td>
<td valign="top" align="center">0.21 ( &#xb1; 0.04)</td>
<td valign="top" align="center">0.22 ( &#xb1; 0.03)</td>
<td valign="top" align="center">0.34 ( &#xb1; 0.04)</td>
<td valign="top" align="center">0.23 ( &#xb1; 0.02)</td>
<td valign="top" align="center">0.22 ( &#xb1; 0.06)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Monocytes</bold>
</td>
<td valign="top" align="center">5.54 ( &#xb1; 0.88)</td>
<td valign="top" align="center">8.41 ( &#xb1; 1.55)</td>
<td valign="top" align="center" style="color:red;">
<bold>1.58 ( &#xb1; 0.21)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>0.81 ( &#xb1; 0.22)</bold>
</td>
<td valign="top" align="center">0.89 ( &#xb1; 0.03)</td>
<td valign="top" align="center">0.84 ( &#xb1; 0.12)</td>
<td valign="top" align="center">0.34 ( &#xb1; 0.16)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>DC CD8 type</bold>
</td>
<td valign="top" align="center">27.5 ( &#xb1; 2.78)</td>
<td valign="top" align="center">20.44 ( &#xb1; 2.19)</td>
<td valign="top" align="center">13.52 ( &#xb1; 1.53)</td>
<td valign="top" align="center">13.17 ( &#xb1; 1.43)</td>
<td valign="top" align="center">43.60 ( &#xb1; 0.70)</td>
<td valign="top" align="center">42.30 ( &#xb1; 1.58)</td>
<td valign="top" align="center">3.69 ( &#xb1; 0.72)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>DC CD11b type</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>1.29 ( &#xb1; 0.28)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>3.31 ( &#xb1; 0.53)</bold>
</td>
<td valign="top" align="center">1.06 ( &#xb1; 0.15)</td>
<td valign="top" align="center">1.35 ( &#xb1; 0.13)</td>
<td valign="top" align="center">1.81 ( &#xb1; 0.17)</td>
<td valign="top" align="center">1.92 ( &#xb1; 0.11)</td>
<td valign="top" align="center">4.54 ( &#xb1; 0.99)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Progenitor DC (pDC)</bold>
</td>
<td valign="top" align="center">7.54 ( &#xb1; 1.96)</td>
<td valign="top" align="center">7.99 ( &#xb1; 1.06)</td>
<td valign="top" align="center">10.65 ( &#xb1; 0.89)</td>
<td valign="top" align="center">11.13 ( &#xb1; 1.36)</td>
<td valign="top" align="center">5.43 ( &#xb1; 0.75)</td>
<td valign="top" align="center">4.50 ( &#xb1; 0.43)</td>
<td valign="top" align="center">6.69 ( &#xb1; 1.46)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>NK cells</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>5.87 ( &#xb1; 0.72)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>10.84 ( &#xb1; 1.71)</bold>
</td>
<td valign="top" align="center">2.80 ( &#xb1; 0.17)</td>
<td valign="top" align="center">0.91 ( &#xb1; 0.23)</td>
<td valign="top" align="center">4.09 ( &#xb1; 0.63)</td>
<td valign="top" align="center">3.12 ( &#xb1; 0.20)</td>
<td valign="top" align="center">0.79 ( &#xb1; 0.35)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>T helper (Th) effector</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>2.63 ( &#xb1; 0.72)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>0.69 ( &#xb1; 0.03)</bold>
</td>
<td valign="top" align="center">0.37 ( &#xb1; 0.13)</td>
<td valign="top" align="center">0.17475 ( &#xb1; 0.12)</td>
<td valign="top" align="center" style="color:red;">
<bold>1.28 ( &#xb1; 0.06)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>0.72 ( &#xb1; 0.01)</bold>
</td>
<td valign="top" align="center">0.22 ( &#xb1; 0.07)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>T helper (Th) resting</bold>
</td>
<td valign="top" align="center">4.49 ( &#xb1; 0.59)</td>
<td valign="top" align="center">4.54 ( &#xb1; 0.68)</td>
<td valign="top" align="center">2.45 ( &#xb1; 0.50)</td>
<td valign="top" align="center">1.22 ( &#xb1; 0.32)</td>
<td valign="top" align="center">7.73 ( &#xb1; 0.71)</td>
<td valign="top" align="center">8.93 ( &#xb1; 0.61)</td>
<td valign="top" align="center">0.16 ( &#xb1; 0.07)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>T regulator (T reg) effector</bold>
</td>
<td valign="top" align="center">0.86 ( &#xb1; 0.08)</td>
<td valign="top" align="center">0.66 ( &#xb1; 0.06)</td>
<td valign="top" align="center">0.68 ( &#xb1; 0.12)</td>
<td valign="top" align="center">0.52 ( &#xb1; 0.12)</td>
<td valign="top" align="center">0.53 ( &#xb1; 0.05)</td>
<td valign="top" align="center">0.46 ( &#xb1; 0.03)</td>
<td valign="top" align="center">0.28 ( &#xb1; 0.08)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>T regulator (T reg) resting</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>0.14 ( &#xb1; 0.02)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>0.43 ( &#xb1; 0.06)</bold>
</td>
<td valign="top" align="center">0.35 ( &#xb1; 0.06)</td>
<td valign="top" align="center">0.22 ( &#xb1; 0.07)</td>
<td valign="top" align="center" style="color:blue;">
<bold>0.82 ( &#xb1; 0.01)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>1.34 ( &#xb1; 0.09)</bold>
</td>
<td valign="top" align="center">0.029 ( &#xb1; 0.01)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>T cytotoxic effector</bold>
</td>
<td valign="top" align="center">0.47 ( &#xb1; 0.09)</td>
<td valign="top" align="center">0.31 ( &#xb1; 0.01)</td>
<td valign="top" align="center">0.31 ( &#xb1; 0.10)</td>
<td valign="top" align="center">0.11 ( &#xb1; 0.03)</td>
<td valign="top" align="center">0.53 ( &#xb1; 0.08)</td>
<td valign="top" align="center">0.34 ( &#xb1; 0.03)</td>
<td valign="top" align="center">0.68 ( &#xb1; 0.27)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>T cytotoxic naive</bold>
</td>
<td valign="top" align="center">3.62 ( &#xb1; 0.67)</td>
<td valign="top" align="center">2.53 ( &#xb1; 0.38)</td>
<td valign="top" align="center" style="color:red;">
<bold>1.25 ( &#xb1; 0.12)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>0.58 ( &#xb1; 0.12)</bold>
</td>
<td valign="top" align="center">5.56 ( &#xb1; 0.73)</td>
<td valign="top" align="center">6.92 ( &#xb1; 0.72)</td>
<td valign="top" align="center">0.07 ( &#xb1; 0.04)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>T cytotoxic resting</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>1.56 ( &#xb1; 0.35)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>0.67 ( &#xb1; 0.12)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>0.44 ( &#xb1; 0.07)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>0.10 ( &#xb1; 0.03)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>2.44 ( &#xb1; 0.25)</bold>
</td>
<td valign="top" align="center"  style="color:red;">
<bold>1.64 ( &#xb1; 0.17)</bold>
</td>
<td valign="top" align="center">0.04 ( &#xb1; 0.02)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>B2 total</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>24.82 ( &#xb1; 2.80)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>11.16 ( &#xb1; 1.22)</bold>
</td>
<td valign="top" align="center">11.53 ( &#xb1; 1.09)</td>
<td valign="top" align="center">9.22 ( &#xb1; 0.91)</td>
<td valign="top" align="center">34.90 ( &#xb1; 1.07)</td>
<td valign="top" align="center">28.87 ( &#xb1; 0.95)</td>
<td valign="top" align="center">1.37 ( &#xb1; 0.34)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>B2 mature</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>2.31 ( &#xb1; 0.25)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>1.55 ( &#xb1; 0.09)</bold>
</td>
<td valign="top" align="center">2.69 ( &#xb1; 0.48)</td>
<td valign="top" align="center">3.75 ( &#xb1; 0.27)</td>
<td valign="top" align="center">3.38 ( &#xb1; 0.28)</td>
<td valign="top" align="center">2.97 ( &#xb1; 0.09)</td>
<td valign="top" align="center">0.26 ( &#xb1; 0.11)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>B2 immature</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>21.98 ( &#xb1; 2.79)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>9.26 ( &#xb1; 1.13)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>8.52 ( &#xb1; 0.85)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>5.14 ( &#xb1; 0.70)</bold>
</td>
<td valign="top" align="center">30.67 ( &#xb1; 0.91)</td>
<td valign="top" align="center">25.20 ( &#xb1; 0.83)</td>
<td valign="top" align="center">1.03 ( &#xb1; 0.23)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>B1 total</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>0.73 ( &#xb1; 0.09)</bold>
</td>
<td valign="top" align="center" style="color:red;">
<bold>0.58 ( &#xb1; 0.03)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>3.14 ( &#xb1; 0.48)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>5.81 ( &#xb1; 0.76)</bold>
</td>
<td valign="top" align="center">3.43 ( &#xb1; 0.38)</td>
<td valign="top" align="center">4.90 ( &#xb1; 0.44)</td>
<td valign="top" align="center">1.74 ( &#xb1; 0.32)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>NKT effector</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>0.77 ( &#xb1; 0.14)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>2.04 ( &#xb1; 0.27)</bold>
</td>
<td valign="top" align="center">12.92 ( &#xb1; 0.88)</td>
<td valign="top" align="center">16.22 ( &#xb1; 2.22)</td>
<td valign="top" align="center">1.29 ( &#xb1; 0.18)</td>
<td valign="top" align="center">0.95 ( &#xb1; 0.07)</td>
<td valign="top" align="center">3.15 ( &#xb1; 0.99)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Invariant NKT (iNKTs)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>0.57 ( &#xb1; 0.07)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>2.23 ( &#xb1; 0.33)</bold>
</td>
<td valign="top" align="center">6.21 ( &#xb1; 1.09)</td>
<td valign="top" align="center">8.98 ( &#xb1; 1.40)</td>
<td valign="top" align="center">1.13 ( &#xb1; 0.24)</td>
<td valign="top" align="center">1.47 ( &#xb1; 0.15)</td>
<td valign="top" align="center">1.99 ( &#xb1; 0.67)</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>NKT resting</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>0.46 ( &#xb1; 0.05)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>1.43 ( &#xb1; 0.16)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>0.96 ( &#xb1; 0.11)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>1.43 ( &#xb1; 0.35)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>0.78 ( &#xb1; 0.11)</bold>
</td>
<td valign="top" align="center" style="color:blue;">
<bold>1.63 ( &#xb1; 0.20)</bold>
</td>
<td valign="top" align="center">0.68 ( &#xb1; 0.17)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Values are the percentage of total live cells. Values in blue are significantly increased whereas those in red are significantly decreased in Jeff Het (Fbxo11<sup>Jf/+</sup>) compared to Jeff Wt (Jeff wild-type) mice. MEF, middle ear fluid; DC, dendritic cell; NK, natural killer cell.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f1" position="float">
<label>Figure 1</label>
<caption>
<p>Natural killer (NK) cell percentage in <italic>Jeff</italic> mice (<italic>Fbxo11<sup>Jf/+</sup>
</italic> and <italic>Jeff</italic> Wt). <bold>(A)</bold> Average difference in the percentage of blood NK cells in <italic>Jeff</italic> Het (<italic>Fbxo11<sup>Jf/+</sup>
</italic>) and <italic>Jeff</italic> wild type (<italic>Jeff</italic> Wt) mice. The error bars show standard error of mean where n = 4 and *P &lt; 0.05. Representative flow cytometry plot for NK cell analysis of bloods from <italic>Jeff</italic> Wt <bold>(B)</bold> and <italic>Jeff</italic> Het (<italic>Fbxo11<sup>Jf/+</sup>
</italic>) <bold>(C)</bold> mice. <bold>(D)</bold> Average difference in the percentage of blood effector NKT, resting NKT, and invariant NKT (iNKT) cells in <italic>Jeff</italic> Het (<italic>Fbxo11<sup>Jf/+</sup>
</italic>) and <italic>Jeff</italic> Wt mice. The error bars show standard error of mean where n = 4 and *P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001. Representative flow cytometry plot for NKT cell analysis of bloods from <italic>Jeff</italic> Wt <bold>(E)</bold> and <italic>Jeff</italic> Het (<italic>Fbxo11<sup>Jf/+</sup>
</italic>) <bold>(F)</bold> mice.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fgene-11-00050-g001.tif"/>
</fig>
<p>A similar analysis carried out on the <italic>Fbxo11<sup>tm2b/+</sup>
</italic> heterozygote <italic>Fbxo11</italic> knockout mouse (<xref ref-type="supplementary-material" rid="SM5">
<bold>Table S3</bold>
</xref>), did not show the major differences in innate immune cell content as observed in the <italic>Fbxo11<sup>Jf/+</sup>
</italic>mouse in comparison to their respective wild-type countertypes. The only significant difference observed for the <italic>Fbxo11<sup>tm2b/+</sup>
</italic> compared to <italic>Fbxo11<sup>+/+</sup>
</italic> mouse was for blood and lung macrophages and blood CD11b+ DC's. <italic>Fbxo11<sup>tm2b/+</sup>
</italic> had a slight but significantly higher percentage of blood macrophages (1.72%) compared to the <italic>Fbxo11<sup>+/+</sup>
</italic> mouse (0.95%). Also, CD11b+ DC's were 3.61% in <italic>Fbxo11<sup>tm2b/+</sup>
</italic> mouse compared to 2.65% in the <italic>Fbxo11<sup>+/+</sup>
</italic> mouse blood. In lungs of the <italic>Fbxo11<sup>tm2b/+</sup>
</italic> mouse, macrophage numbers were significantly elevated (0.86%) compared to its wild-type counterpart, <italic>Fbxo11<sup>+/+</sup>
</italic> (0.39%). We observed minor immune cell differences between the <italic>Jeff</italic> wild-type and <italic>Fbxo11<sup>+/+</sup>
</italic> wild-type mice. It is known that mouse background affects immunity and the mouse immune response to infection. The <italic>Jeff</italic> wild-type and <italic>Fbxo11<sup>+/+</sup>
</italic> mouse vary in their background: <italic>Jeff</italic> wild-type is on mixed C57BL/6J C3H/HeH background whereas the <italic>Fbxo11<sup>+/+</sup>
</italic> mouse is on a C57BL/6NJ background, we predict that this difference in background could be influencing the difference in immune cell content observed between these wild-types.</p>
<p>Our observed differences in innate immune cells between the <italic>Fbxo11<sup>Jf/+</sup>
</italic> and the <italic>Fbxo11<sup>tm2b/+</sup>
</italic> mouse indicates the significant role played by the <italic>Fbxo11</italic> gene in immunogenetic control of these cells and OM.</p>
</sec>
<sec id="s3_2">
<title>Adaptive Immune Cell Population in <italic>Jeff</italic> Mouse</title>
<p>We characterized the content of adaptive immune cells (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>): T cells (helper and cytotoxic), B cells, and natural killer T (NKT) cells in <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse blood, lung, spleen, and middle ear fluid. The percentage of T helper (Th) effector cells in the blood was significantly less in <italic>Fbxo11<sup>Jf/+</sup>
</italic> (0.69%) compared to the <italic>Jeff</italic> wild-type counterpart. The percentage of blood resting T cytotoxic cells was also significantly less in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> (0.67%) compared to <italic>Jeff</italic> wild-type (1.56%) mouse. In contrast, the percentage of blood T regulatory (T reg) resting cells was significantly higher in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> compared to <italic>Jeff</italic> wild-type mouse. The greatest difference was observed in the proportion of blood immature B cells; <italic>Fbxo11<sup>Jf/+</sup>
</italic> had significantly less (9.26%) immature B cells compared to the <italic>Jeff</italic> wild-type (21.98%) mouse (<xref ref-type="fig" rid="f2">
<bold>Figure 2A&#x2013;C</bold>
</xref>). In contrast, NKT cell levels in the blood were significantly higher in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> compared to <italic>Jeff</italic> wild-type mouse. <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse blood had a significantly higher level of effector NKT cells, 2.04% compared to 0.77% in <italic>Jeff</italic> wild-type. A similar trend was observed in the levels of resting NKT cells and invariant NKT (iNKT) cells (<xref ref-type="fig" rid="f1">
<bold>Figure 1D&#x2013;F</bold>
</xref>, <xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure 2</label>
<caption>
<p>B cell percentage in <italic>Jeff</italic> mice (<italic>Fbxo11<sup>Jf/+</sup>
</italic> and <italic>Jeff</italic> Wt). <bold>(A)</bold> Average difference in the percentage of mature and immature blood B2 cells in <italic>Jeff</italic> Het (<italic>Fbxo11<sup>Jf/+</sup>
</italic>) and <italic>Jeff</italic> Wt mice. The error bars show standard error of mean where n = 4 and *P &lt; 0.05, **P &lt; 0.01. Representative flow cytometry plot for B cell analysis of bloods from <italic>Jeff</italic> Wt <bold>(B)</bold> and <italic>Jeff</italic> Het (<italic>Fbxo11<sup>Jf/+</sup>
</italic>) <bold>(C)</bold> mice.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fgene-11-00050-g002.tif"/>
</fig>
<p>Analysis of cells derived from the lung did not show a significant difference in T-helper cells, but a significant reduction in the levels of na&#xef;ve and resting T-cytotoxic cells was observed in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> compared to the <italic>Jeff</italic> wild-type mouse. The <italic>Fbxo11<sup>Jf/+</sup>
</italic> lung had 0.58 and 0.1% of na&#xef;ve and resting T cytotoxic cells respectively compared to 1.25 and 0.44% (na&#xef;ve and resting respectively) in <italic>Jeff</italic> wild-type. Other than T-cytotoxic cells, the only significant reduction observed was in B2-immature cells; the <italic>Fbxo11<sup>Jf/+</sup>
</italic> lung had 5.14% of B2-immature cells compared to 8.52% in the <italic>Jeff</italic> wild-type mouse. The percent of effector Th cells was significantly lower (0.72%) in <italic>Fbxo11<sup>Jf/+</sup>
</italic> compared to 1.28% observed in the <italic>Jeff</italic> wild-type mouse whereas the resting T reg percentage was significantly higher in <italic>Fbxo11<sup>Jf/+</sup>
</italic> spleen (1.34%) compared to that found in <italic>Jeff</italic> wild-type (0.82%). Also, a higher percentage of resting NKT cells was observed in <italic>Fbxo11<sup>Jf/+</sup>
</italic> spleen (1.63%) compared to its wild-type counterpart (0.78%). In the middle ear fluid, the highest percentage of adaptive immune cells observed was NKT cells at 5.83%; among these NKT cells nearly 55% were effector cells. After NKT cells, B cells were the second highest adaptive immune cells observed in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse middle ear fluid. The percentages of B1 and B2 cells in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> middle ear fluid were 1.74 and 1.37%, respectively and nearly 75% of the B2 cells were mature (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>).</p>
<p>Similar analysis carried out on the <italic>Fbxo11<sup>tm2b/+</sup>
</italic> knockout mouse did not show major differences in adaptive immune cells as had been observed for the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse compared to the respective wild type (<xref ref-type="supplementary-material" rid="SM5">
<bold>Table S3</bold>
</xref>). Other than splenic immature B2 cells, no other significant differences were observed in the <italic>Fbxo11<sup>tm2b/+</sup>
</italic> knockout compared to its wild-type counterpart <italic>Fbxo11<sup>+/+</sup>
</italic>mouse. The <italic>Fbxo11<sup>tm2b/+</sup>
</italic> mouse spleen had a significantly higher proportion of immature B2 cells (16.23%) compared to its wild-type counterpart <italic>Fbxo11<sup>+/+</sup>
</italic> (8.60%). Our analysis indicates that the mutation in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse affects not only the innate immune cell content but also adaptive immune cells. The absence of cellular immune changes in the <italic>Fbxo11<sup>tm2b/+</sup>
</italic> mouse that were observed in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse suggests that the ENU mutation in the <italic>Fbxo11</italic> gene could be gain of function which alters the regulation of immune cells, leading to lung and middle ear phenotypes observed in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mice.</p>
</sec>
<sec id="s3_3">
<title>Cytokine/Chemokine Levels in <italic>Jeff</italic> Mouse</title>
<p>Mutation in the <italic>Fbxo11</italic> gene leads to systemic and local differences in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse immune cells. To understand the influence of the autocrine and paracrine signals on the differences observed, levels of the specific cytokines/chemokines that modulate the functional response in the immune cells were analyzed (<xref ref-type="fig" rid="f3">
<bold>Figure 3A</bold>
</xref>). A significant increase in G-CSF, GM-CSF, sTNFRI (soluble TNFRI), and TPO levels was observed in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> serum compared to the <italic>Jeff</italic> wild-type. The significant increase in the NK cells observed in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse could correlate with the major cytokines known to modulate NK cell number and function, IL-7 and IL-15 (<xref ref-type="fig" rid="f3">
<bold>Figure 3B</bold>
</xref>). Of these two cytokines, only IL-7 was significantly higher in <italic>Fbxo11<sup>Jf/+</sup>
</italic> serum compared to its wild-type counterpart mouse. A majority of the cytokine/chemokines in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse middle ear fluid were relatively high: IL-12p40/p70, IL-12p70, CCL2, sTNFRI, and TPO. High levels of IL-7 were also observed in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> middle ear fluid.</p>
<fig id="f3" position="float">
<label>Figure 3</label>
<caption>
<p>Cytokine and chemokine levels in <italic>Jeff</italic> mouse (<italic>Fbxo11<sup>Jf/+</sup>
</italic> and <italic>Jeff</italic> Wt) serum and middle ear fluid (MEF). <bold>(A)</bold> The volume coverage represents the cytokine/chemokine levels obtained after analyses of 10 &#xb5;l serum from <italic>Jeff</italic> Het (<italic>Fbxo11<sup>Jf/+</sup>
</italic>) and <italic>Jeff</italic> Wt and 1 &#xb5;l MEF from <italic>Jeff</italic> Het (<italic>Fbxo11<sup>Jf/+</sup>
</italic>). Volume cover was calculated using Image Lab (BioRadTM) analysis on the RayBioRc C-Series mouse cytokine antibody array C1. <bold>(B)</bold> Interleukin (IL)-7 and IL-15 levels in the serum from <italic>Jeff</italic> Het (<italic>Fbxo11<sup>Jf/+</sup>
</italic>) and <italic>Jeff</italic> Wt and MEF from <italic>Jeff</italic> Het (<italic>Fbxo11<sup>Jf/+</sup>
</italic>), using mouse IL-7 or IL-15 DuoSet ELISA (R&amp;D systems&#x2122;). The concentrations in pg/ml were obtained from the standard graph of concentration against absorbance at 450 nm. The error bars show standard error of mean where n = 4 and *P &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fgene-11-00050-g003.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>One of the best characterized animal models for chronic OM is the <italic>Jeff</italic> mouse mutant, which carries a mutation in the <italic>Fbxo11</italic> gene that is known to be associated with human OM (<xref ref-type="bibr" rid="B6">Hardisty et&#xa0;al., 2003</xref>; <xref ref-type="bibr" rid="B26">Segade et&#xa0;al., 2006</xref>; <xref ref-type="bibr" rid="B2">Bhutta et&#xa0;al., 2017a</xref>). To understand the effect of this mutation on the systemic and localized immune cell content, we analyzed the immune cell population in the <italic>Jeff</italic> mutant mouse.</p>
<p>The most significant difference observed between <italic>Jeff</italic> heterozygotes (<italic>Fbxo11<sup>Jf/+</sup>
</italic>) and wild-type mice was in the increased percentage of NK cells in blood, which are significantly raised in the mutant. Similarly, the percentage of NKT cells (effector, resting, and iNKT) was high in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> compared to the wild-type mouse. Analysis carried out on otitis-prone children has shown similar findings; children prone to OM have a higher proportion of NK cells in blood compared to a healthy control group. The authors of the study postulate that the increase in NK cell numbers is due to prolonged exposure to upper respiratory tract infection (<xref ref-type="bibr" rid="B27">Seppanen et&#xa0;al., 2018</xref>). However, our current study provides the possibility of a genetic link being responsible for the increase in the circulating NK cells. The <italic>Fbxo11<sup>Jf/+</sup>
</italic> mice utilized in the present study are bred in specific pathogen-free conditions (<xref ref-type="bibr" rid="B9">Hood et&#xa0;al., 2016</xref>). The development of OM in <italic>Fbxo11<sup>Jf/+</sup>
</italic> mice is spontaneous at a young age (<xref ref-type="bibr" rid="B6">Hardisty et&#xa0;al., 2003</xref>). A similar analysis carried out in the <italic>Fbxo11<sup>tm2b/+</sup>
</italic> knockout mouse did not show any difference in the NK cell population when compared to its wild-type counterpart. This indicates that the increase in the NK cells in the circulation can be purely attributed to the specific mutation in the <italic>Fbxo11</italic> gene in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse.</p>
<p>One of the major cytokines that plays a critical role in NK cell development, homeostasis, and activation is IL-15 (<xref ref-type="bibr" rid="B16">Mar&#xe7;ais et&#xa0;al., 2013</xref>). Mice deficient in IL-15 do not produce NK cells, supporting its significance in NK cell development (<xref ref-type="bibr" rid="B20">Ranson et&#xa0;al., 2003</xref>). Analysis of IL-15 levels in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse serum did not show a significant difference compared to its wild-type counterpart indicating that the <italic>Fbxo11</italic> mutation does not affect the paracrine signaling for NK cell modulation through IL-15. IL-15 maintains the peripheral NK cell numbers by increasing the anti-apoptotic BCL6 family proteins (<xref ref-type="bibr" rid="B20">Ranson et&#xa0;al., 2003</xref>). BCL6 is targeted for ubiquitination and proteasomal degradation by an SKP1&#x2013;CUL1&#x2013;F- box protein (SCF) ubiquitin ligase complex that contains the FBXO11 protein (<xref ref-type="bibr" rid="B5">Duan et&#xa0;al., 2012</xref>). The increased blood NK cell percentage in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse indicates the possible alteration of the SCF mediated BCL6 degradation, specifically in the NK cells. Another important cytokine that regulates NK cell function is TGF-beta, levels of which were not significantly different in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse compared to its wild-type counterpart. Earlier studies carried out on the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse have highlighted the significance of the <italic>Jeff</italic> mutation on the Smad2 mediated TGF-beta induced intracellular signaling in the developmental pathways (<xref ref-type="bibr" rid="B28">Tateossian et&#xa0;al., 2009</xref>). Even though we did not observe any significant difference in the levels of TGF-beta in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse, the intracellular signaling induced by TGF-beta in the NK cells could play a vital role in their increased levels and function.</p>
<p>Along with NK cells, we also observed a significant increase in the circulating T cell population in the <italic>Fbxo11<sup>Jf/+</sup>
</italic>mouse. One of the cytokines that can stimulate the release of lymphocytes from bone marrow and thymus is IL-7 (<xref ref-type="bibr" rid="B32">von Freeden-Jeffry et&#xa0;al., 1995</xref>); levels of this cytokine were significantly higher in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> serum compared to its wild-type counterpart. Along with increasing lymphocyte numbers, this elevated level of IL-7 can also result in increased thymic NK cell numbers (<xref ref-type="bibr" rid="B16">Mar&#xe7;ais et&#xa0;al., 2013</xref>). IL-7 also increases the release of B cells from bone marrow and thymus (<xref ref-type="bibr" rid="B32">von Freeden-Jeffry et&#xa0;al., 1995</xref>) but in <italic>Fbxo11<sup>Jf/+</sup>
</italic> the percentage of B cells was significantly lower than in the wild-type mouse. FBXO11 is known to play a critical role in maintenance of B cell levels <italic>via</italic> the BCL6 pathway and FBXO11 loss of function is frequently observed in B cell lymphoma cell lines and increased B-cell levels (<xref ref-type="bibr" rid="B5">Duan et&#xa0;al., 2012</xref>), as we observed in the <italic>Fbxo11<sup>tmb2/+</sup>
</italic> knockout mouse. Restoration of BCL6 function in the B cell lymphoma cell lines has been shown to inhibit B-cell lymphogensis (<xref ref-type="bibr" rid="B5">Duan et&#xa0;al., 2012</xref>), indicating a potential critical role played by FBXO11 in the modulation of B cell survival. Our observation of reduced levels of B cells in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse indicates that the <italic>Jeff</italic> mutation in the B-cells could be inducing the apoptotic pathways, possibly through BCL6. This novel role of <italic>Fbxo11</italic> in the modulation of B cell survival warrants further studies but suggest that the <italic>Jeff</italic> mutation may be manifesting gain of function phenotypes in the regulation of B cell numbers.</p>
<p>The other cytokines that were significantly increased in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> serum compared to wild-type were G-CSF and GM-CSF. Both these cytokines play a critical role in the regulation of neutrophil development (<xref ref-type="bibr" rid="B21">Roberts, 2005</xref>), which could correspond with the significantly higher blood granulocyte levels observed in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse. G-CSF also inhibits NK cell activity (<xref ref-type="bibr" rid="B25">Schlahsa et&#xa0;al., 2011</xref>). IL-2 is one of the major cytokines released after activation of NK cells. In the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse, even with the high percentage of NK cells in the circulation, no difference in IL-2 levels was observed compared to wild type. Neutrophil numbers also play a critical role in perturbation of inflammation in the middle ear. In other animal models, the extracellular neutrophil DNA in the middle ear fluid contributes to NTHi biofilm formation (<xref ref-type="bibr" rid="B12">Jurcisek and Bakaletz, 2007</xref>; <xref ref-type="bibr" rid="B11">Juneau et&#xa0;al., 2011</xref>). In the case of <italic>Fbxo11<sup>Jf/+</sup>
</italic> mice, the neutrophil percentage in the middle ear fluid was high and most of these were living. This might be a contributing factor toward the significantly lower NTHi titers and infection rate observed in <italic>Fbxo11<sup>Jf/+</sup>
</italic> compared to <italic>Junbo</italic> mice (<xref ref-type="bibr" rid="B9">Hood et&#xa0;al., 2016</xref>); the latter has high levels of necrotic cells in the middle ear fluid (<xref ref-type="bibr" rid="B31">Vikhe et&#xa0;al., 2019</xref>).</p>
<p>The level of soluble TNFRI (sTNFR1) in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> serum was significantly higher than that found in wild-type, whereas TNF&#x2013;alpha levels were not different. sTNFRI has a high affinity for TNF-alpha (<xref ref-type="bibr" rid="B34">Wang et&#xa0;al., 2004</xref>), modulating its slow release and thus suppressing inflammation. It is well established that inhibiting TNF-alpha decreases middle ear inflammation in OM (<xref ref-type="bibr" rid="B10">Jeun et&#xa0;al., 2001</xref>). Trans-tympanic membrane treatment of mice with sTNFRI and anti-TNF-alpha inhibits LPS induced middle ear inflammation and OM (<xref ref-type="bibr" rid="B10">Jeun et&#xa0;al., 2001</xref>). The molecular level regulation for the release of sTNFRI is still unclear. The increase in sTNFRI in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse serum indicates a role for FBXO11 in its regulation; this mouse model could play an essential role in understanding the regulation of this critical cytokine at the genetic level.</p>
<p>Another cytokine/growth factor that was significantly higher in <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse serum was thrombopoietin (TPO). TPO is a growth factor that initiates the process of megakaryocyte production and generation of platelets (<xref ref-type="bibr" rid="B15">Lupia et&#xa0;al., 2012</xref>). Increased levels of TPO are found in patients with inflammatory bowel disease (<xref ref-type="bibr" rid="B13">Kapsoritakis et&#xa0;al., 2000</xref>) and <italic>Streptococcus pneumoniae</italic> induced bacterial meningitis in mice (<xref ref-type="bibr" rid="B8">Hoffmann et&#xa0;al., 2011</xref>). The relevance of TPO in cardiovascular damage and inflammatory diseases is known (<xref ref-type="bibr" rid="B15">Lupia et&#xa0;al., 2012</xref>), but its role in OM has yet to be evaluated. We were not able to classify platelet population in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mouse in our current study but increased levels of TPO are indicative of abnormal platelet function and its relevance in OM can be investigated using this mutant mouse model.</p>
<p>In conclusion, our studies of the <italic>Jeff</italic> (<italic>Fbxo11<sup>Jf/+</sup>
</italic>) mouse model identify immune cell changes which can play a critical role in inflammation. A significant increase in blood neutrophil, NK cells, NKT cells and dendritic cells were observed in the <italic>Fbxo11<sup>Jf/+</sup>
</italic> mutant mouse compared to wild-type. The heterozygote <italic>Fbxo11</italic> knockout mouse did not show these differences, consistent with a gain of function for the <italic>Jeff</italic> mutation that leads to these immune cell changes. Interestingly, as we report elsewhere (Kubinyecz <italic>et al</italic>. manuscript submitted), the <italic>Fbxo11<sup>tm2b/+</sup>
</italic> heterozygous knockout mouse does not develop a spontaneous OM phenotype as observed in <italic>Fbxo11<sup>Jf/+</sup>
</italic>, which is also indicative of gain of function effects. In conclusion, this study paves the way for further studies using the <italic>Jeff</italic> model to dissect the genetic interrelationships between the control of immune cells and OM.</p>
</sec>
<sec id="s5">
<title>Data Availability Statement</title>
<p>All datasets generated for this study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by MRC Harwell Institute ethics review committee and this study was carried out under the appropriate UK Home Office license.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>PV designed and conceptualized the experiments. PV, HT, and GB performed the experiments. PV, and GB analyzed the data. PV and HT participated in collecting animals testes. PV drafted the manuscript. PV, HT, DH, and SB edited and wrote the final manuscript. All authors approved the manuscript for submission.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>This work was funded by the Medical Research Council (MRC funding award no. MC_U142684175).</p>
</sec>
<sec id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank the staff in the Mary Lyon Centre for the husbandry and humane care of these mice, clinical chemistry, pathology and histology teams, and the genotyping core, at MRC Harwell Institute.</p>
</ack>
<sec id="s10" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fgene.2020.00050/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2020.00050/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image_1.pdf" id="SM1" mimetype="application/pdf">
<label>Figure S1</label>
<caption>
<p>Flow cytometry panel 1 gating strategy.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image_2.pdf" id="SM2" mimetype="application/pdf">
<label>Figure S2</label>
<caption>
<p>Flow cytometry panel 2 gating strategy.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Table_1.pdf" id="SM3" mimetype="application/pdf">
<label>Table S1</label>
<caption>
<p>Flow cytometry antibody and panels.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Table_2.pdf" id="SM4" mimetype="application/pdf">
<label>Table S2</label>
<caption>
<p>Flow cytometry gating strategy.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Table_3.pdf" id="SM5" mimetype="application/pdf">
<label>Table S3</label>
<caption>
<p>Immune cell percentage in <italic>Fbxo11<sup>tmb2/+</sup></italic> (<italic>Fbxo11</italic> knockout) and <italic>Fbxo11<sup>+/+</sup></italic> mouse obtained by flow cytometry.</p>
</caption>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abida</surname> <given-names>W. M.</given-names>
</name>
<name>
<surname>Nikolaev</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>W.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity</article-title>. <source>J. Biol. Chem.</source> <volume>282</volume>, <fpage>1797</fpage>&#x2013;<lpage>1804</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M609001200</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhutta</surname> <given-names>M. F.</given-names>
</name>
<name>
<surname>Lambie</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Hobson</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Goel</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Hafr&#xe9;n</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Einarsdottir</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>a). <article-title>A mouse-to-man candidate gene study identifies association of chronic otitis media with the loci TGIF1 and FBXO11</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>18</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-017-12784-8</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhutta</surname> <given-names>M. F.</given-names>
</name>
<name>
<surname>Thornton</surname> <given-names>R. B.</given-names>
</name>
<name>
<surname>Kirkham</surname> <given-names>L.-A. S.</given-names>
</name>
<name>
<surname>Kerschner</surname> <given-names>J. E.</given-names>
</name>
<name>
<surname>Cheeseman</surname> <given-names>M. T.</given-names>
</name>
</person-group> (<year>2017</year>b). <article-title>Understanding the aetiology and resolution of chronic otitis media from animal and human studies</article-title>. <source>Dis. Model. Mech.</source> <volume>10</volume>, <fpage>1289</fpage>&#x2013;<lpage>1300</lpage>. doi: <pub-id pub-id-type="doi">10.1242/dmm.029983</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crompton</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Purnell</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Tyrer</surname> <given-names>H. E.</given-names>
</name>
<name>
<surname>Parker</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Ball</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Hardisty-Hughes</surname> <given-names>R. E.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>A mutation in Nischarin causes otitis media via LIMK1 and NF-&#x3ba;B pathways</article-title>. <source>PloS Genet</source>. <volume>13</volume> (<issue>8</issue>), <elocation-id>e1006969</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pgen.1006969</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Cermak</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Pagan</surname> <given-names>J. K.</given-names>
</name>
<name>
<surname>Rossi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Martinengo</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Celle</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>FBXO11 targets BCL6 for degradation andis inactivated in diffuse large B-cell lymphomas</article-title>. <source>Nature.</source> <volume>481</volume>, <fpage>90</fpage>&#x2013;<lpage>94</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature10688</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardisty</surname> <given-names>R. E.</given-names>
</name>
<name>
<surname>Erven</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Logan</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Morse</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Guionaud</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Sancho-Oliver</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2003</year>). <article-title>The deaf mouse mutant Jeff (Jf) is a single gene model of otitis media</article-title>. <source>J. Assoc. Res. Otolaryngol.</source> <volume>4</volume>, <fpage>130</fpage>&#x2013;<lpage>138</lpage>. doi: <pub-id pub-id-type="doi">10.1007/S10162-002-3015-9</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardisty-Hughes</surname> <given-names>R. E.</given-names>
</name>
<name>
<surname>Tateossian</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Morse</surname> <given-names>S. A.</given-names>
</name>
<name>
<surname>Romero</surname> <given-names>M. R.</given-names>
</name>
<name>
<surname>Middleton</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Tymowska-Lalanne</surname> <given-names>Z.</given-names>
</name>
<etal/>
</person-group>. (<year>2006</year>). <article-title>A mutation in the F-box gene, Fbxo11, causes otitis media in the Jeff mouse</article-title>. <source>Hum. Mol. Genet.</source> <volume>15</volume>, <fpage>3273</fpage>&#x2013;<lpage>3279</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddl403</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Rung</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Im</surname> <given-names>A.-R.</given-names>
</name>
<name>
<surname>Freyer</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Held</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>Thrombopoietin contributes to neuronal damage in experimental bacterial meningitis</article-title>. <source>Infect. Immun.</source> <volume>79</volume>, <fpage>928</fpage>&#x2013;<lpage>936</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.00782-10</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hood</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Moxon</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Purnell</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Richter</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Azar</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>A new model for non-typeable Haemophilus influenzae middle ear infection in the Junbo mutant mouse</article-title>. <source>Dis. Model. Mech.</source> <volume>9</volume>, <fpage>69</fpage>&#x2013;<lpage>79</lpage>. doi: <pub-id pub-id-type="doi">10.1242/dmm.021659</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeun</surname> <given-names>E.-J.</given-names>
</name>
<name>
<surname>Park</surname> <given-names>Y.-S.</given-names>
</name>
<name>
<surname>Yeo</surname> <given-names>S. W.</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>Y.-C.</given-names>
</name>
<name>
<surname>Jung</surname> <given-names>T. T. K.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Effect of inhibitor of tumor necrosis factor-alpha on experimental otitis media with effusion</article-title>. <source>Ann. Otol. Rhinol. Laryngol.</source> <volume>110</volume>, <fpage>917</fpage>&#x2013;<lpage>921</lpage>. doi: <pub-id pub-id-type="doi">10.1177/000348940111001005</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juneau</surname> <given-names>R. A.</given-names>
</name>
<name>
<surname>Pang</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Weimer</surname> <given-names>K. E. D.</given-names>
</name>
<name>
<surname>Armbruster</surname> <given-names>C. E.</given-names>
</name>
<name>
<surname>Swords</surname> <given-names>W. E.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Nontypeable Haemophilus influenzae initiates formation of neutrophil extracellular traps</article-title>. <source>Infect. Immun.</source> <volume>79</volume>, <fpage>431</fpage>&#x2013;<lpage>438</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.00660-10</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jurcisek</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Bakaletz</surname> <given-names>L. O.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Biofilms formed by nontypeable Haemophilus influenzae in vivo contain both double-stranded DNA and type IV pilin protein</article-title>. <source>J. Bacteriol.</source> <volume>189</volume>, <fpage>3868</fpage>&#x2013;<lpage>3875</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.01935-06</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapsoritakis</surname> <given-names>A. N.</given-names>
</name>
<name>
<surname>Potamianos</surname> <given-names>S. P.</given-names>
</name>
<name>
<surname>Sfiridaki</surname> <given-names>A. I.</given-names>
</name>
<name>
<surname>Koukourakis</surname> <given-names>M. I.</given-names>
</name>
<name>
<surname>Koutroubakis</surname> <given-names>I. E.</given-names>
</name>
<name>
<surname>Roussomoustakaki</surname> <given-names>M. I.</given-names>
</name>
<etal/>
</person-group>. (<year>2000</year>). <article-title>Elevated thrombopoietin serum levels in patients with inflammatory bowel disease</article-title>. <source>Am. J. Gastroenterol.</source> <volume>95</volume>, <fpage>3478</fpage>&#x2013;<lpage>3481</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1572-0241.2000.03364.x</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>J.-D.</given-names>
</name>
<name>
<surname>Hermansson</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Ryan</surname> <given-names>A. F.</given-names>
</name>
<name>
<surname>Bakaletz</surname> <given-names>L. O.</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>S. D.</given-names>
</name>
<name>
<surname>Cheeseman</surname> <given-names>M. T.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Panel 4: recent advances in otitis media in molecular biology, biochemistry, genetics, and animal models</article-title>. <source>Otolaryngol. Head. Neck Surg.</source> <volume>148</volume>, <fpage>E52</fpage>&#x2013;<lpage>E63</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0194599813479772</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lupia</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Goffi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Bosco</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Montrucchio</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases</article-title>. <source>Mediators Inflamm.</source> <volume>2012</volume>, <fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2012/390892</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mar&#xe7;ais</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Viel</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Grau</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Henry</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Marvel</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Walzer</surname> <given-names>T.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Regulation of mouse NK cell development and function by cytokines</article-title>. <source>Front. Immunol.</source> <volume>4</volume>, <elocation-id>450</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2013.00450</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mittal</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Kodiyan</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Gerring</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Mathee</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J.-D.</given-names>
</name>
<name>
<surname>Grati</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Role of innate immunity in the pathogenesis of otitis media</article-title>. <source>Int. J. Infect. Dis.</source> <volume>29</volume>, <fpage>259</fpage>&#x2013;<lpage>267</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2014.10.015</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nolan</surname> <given-names>P. M.</given-names>
</name>
<name>
<surname>Peters</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Strivens</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Rogers</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Hagan</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Spurr</surname> <given-names>N.</given-names>
</name>
<etal/>
</person-group>. (<year>2000</year>). <article-title>A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse</article-title>. <source>Nat. Genet.</source> <volume>25</volume>, <fpage>440</fpage>&#x2013;<lpage>443</lpage>. doi: <pub-id pub-id-type="doi">10.1038/78140</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parkinson</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Hardisty-Hughes</surname> <given-names>R. E.</given-names>
</name>
<name>
<surname>Tateossian</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Tsai</surname> <given-names>H. T.</given-names>
</name>
<name>
<surname>Brooker</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Morse</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2006</year>). <article-title>Mutation at the Evi1 locus in Junbo mice causes susceptibility to otitis media</article-title>. <source>PloS Genet.</source> <volume>2</volume>, <fpage>1556</fpage>&#x2013;<lpage>1564</lpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pgen.0020149</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranson</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Vosshenrich</surname> <given-names>C. A. J.</given-names>
</name>
<name>
<surname>Corcuff</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Richard</surname> <given-names>O.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Di Santo</surname> <given-names>J. P.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>IL-15 is an essential mediator of peripheral NK-cell homeostasis</article-title>. <source>Blood</source> <volume>101</volume>, <fpage>4887</fpage>&#x2013;<lpage>4893</lpage>. doi: <pub-id pub-id-type="doi">10.1182/blood-2002-11-3392</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberts</surname> <given-names>A. W.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>G-CSF: a key regulator of neutrophil production, but that's not all!</article-title> <source>Growth Factors</source> <volume>23</volume>, <fpage>33</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1080/08977190500055836</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rye</surname> <given-names>M. S.</given-names>
</name>
<name>
<surname>Wiertsema</surname> <given-names>S. P.</given-names>
</name>
<name>
<surname>Scaman</surname> <given-names>E. S. H.</given-names>
</name>
<name>
<surname>Oommen</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Francis</surname> <given-names>R. W.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>FBXO11, a regulator of the TGF&#x3b2; pathway, is associated with severe otitis media in Western Australian children</article-title>. <source>Genes Immun.</source> <volume>12</volume>, <fpage>352</fpage>&#x2013;<lpage>359</lpage>. doi: <pub-id pub-id-type="doi">10.1038/gene.2011.2</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sale</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>W.-M.</given-names>
</name>
<name>
<surname>Weeks</surname> <given-names>D. E.</given-names>
</name>
<name>
<surname>Mychaleckyj</surname> <given-names>J. C.</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Marion</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>Evaluation of 15 functional candidate genes for association with chronic otitis media with effusion and/or recurrent otitis media (COME/ROM)</article-title>. <source>PloS One</source> <volume>6</volume>, <fpage>e22297</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0022297</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schilder</surname> <given-names>A. G. M.</given-names>
</name>
<name>
<surname>Chonmaitree</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Cripps</surname> <given-names>A. W.</given-names>
</name>
<name>
<surname>Rosenfeld</surname> <given-names>R. M.</given-names>
</name>
<name>
<surname>Casselbrant</surname> <given-names>M. L.</given-names>
</name>
<name>
<surname>Haggard</surname> <given-names>M. P.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Otitis media</article-title>. <source>Nat. Rev. Dis. Prim.</source> <volume>2</volume>, <fpage>16063</fpage>. doi: <pub-id pub-id-type="doi">10.1038/nrdp.2016.63</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schlahsa</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Jaimes</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Blasczyk</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Figueiredo</surname> <given-names>C.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Granulocyte-colony-stimulatory factor: a strong inhibitor of natural killer cell function</article-title>. <source>Transfusion</source> <volume>51</volume>, <fpage>293</fpage>&#x2013;<lpage>305</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1537-2995.2010.02820.x</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segade</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Daly</surname> <given-names>K. A.</given-names>
</name>
<name>
<surname>Allred</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Hicks</surname> <given-names>P. J.</given-names>
</name>
<name>
<surname>Cox</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2006</year>). <article-title>Association of the FBXO11 gene with chronic otitis media with effusion and recurrent otitis media: the Minnesota COME/ROM Family Study</article-title>. <source>Arch. Otolaryngol. Head. Neck Surg.</source> <volume>132</volume>, <fpage>729</fpage>&#x2013;<lpage>733</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archotol.132.7.729</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seppanen</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Corscadden</surname> <given-names>K. J.</given-names>
</name>
<name>
<surname>Currie</surname> <given-names>A. J.</given-names>
</name>
<name>
<surname>Richmond</surname> <given-names>P. C.</given-names>
</name>
<name>
<surname>Thornton</surname> <given-names>R. B.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Evidence of functional cell-mediated immune responses to nontypeable Haemophilus influenzae in otitis-prone children</article-title>. <source>PloS One</source> <volume>13</volume>, <fpage>e0193962</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0193962</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tateossian</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Hardisty-Hughes</surname> <given-names>R. E.</given-names>
</name>
<name>
<surname>Morse</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Romero</surname> <given-names>M. R.</given-names>
</name>
<name>
<surname>Hilton</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Dean</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>Regulation of TGF-&#x3b2; signalling by Fbxo11, the gene mutated in the Jeff otitis media mouse mutant</article-title>. <source>Pathogenetics</source> <volume>2</volume>, <fpage>5</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1755-8417-2-5</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tateossian</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Morse</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Simon</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Dean</surname> <given-names>C. H.</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>S. D. M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Interactions between the otitis media gene, Fbxo11, and p53 in the mouse embryonic lung</article-title>. <source>Dis. Model. Mech.</source> <volume>8</volume>, <fpage>1531</fpage>&#x2013;<lpage>1542</lpage>. doi: <pub-id pub-id-type="doi">10.1242/dmm.022426</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veenhoven</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Bogaert</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Uiterwaal</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Brouwer</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Kiezebrink</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Bruin</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2003</year>). <article-title>Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study</article-title>. <source>Lancet</source> <volume>361</volume>, <fpage>2189</fpage>&#x2013;<lpage>2195</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13772-5</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vikhe</surname> <given-names>P. P.</given-names>
</name>
<name>
<surname>Purnell</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>S. D. M.</given-names>
</name>
<name>
<surname>Hood</surname> <given-names>D. W.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Cellular content plays a crucial role in Non-typeable Haemophilus influenzae infection of preinflamed Junbo mouse middle ear</article-title>. <source>Cell. Microbiol.</source> <volume>21</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1111/cmi.12960</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Freeden-Jeffry</surname> <given-names>U.</given-names>
</name>
<name>
<surname>Vieira</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Lucian</surname> <given-names>L. A.</given-names>
</name>
<name>
<surname>McNeil</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Burdach</surname> <given-names>S. E.</given-names>
</name>
<name>
<surname>Murray</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine</article-title>. <source>J. Exp. Med.</source> <volume>181</volume>, <fpage>1519</fpage>&#x2013;<lpage>1526</lpage>. doi: <pub-id pub-id-type="doi">10.1084/jem.181.4.1519</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname> <given-names>Y. Y.</given-names>
</name>
<name>
<surname>Flavell</surname> <given-names>R. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Yin-Yang functions of transforming growth factor-beta and T regulatory cells in immune regulation</article-title>. <source>Immunol. Rev.</source> <volume>220</volume>, <fpage>199</fpage>&#x2013;<lpage>213</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-065X.2007.00565.x</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Tsai</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J.-F.</given-names>
</name>
<name>
<surname>Turrentine</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>J. W.</given-names>
</name>
<etal/>
</person-group>. (<year>2004</year>). <article-title>Preconditioning up-regulates the soluble TNF receptor I response to endotoxin</article-title>. <source>J. Surg. Res.</source> <volume>121</volume>, <fpage>20</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jss.2004.02.017</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Zha</surname> <given-names>Y.-L.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Blanco</surname> <given-names>M. A.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis</article-title>. <source>Cancer Cell</source> <volume>26</volume>, <fpage>358</fpage>&#x2013;<lpage>373</lpage>. doi: <pub-id pub-id-type="doi">10.1016/J.CCR.2014.07.022</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>